INTRODUCTION AND OBJECTIVES: DNA promoter hypermethylation (Confirm MDX) may pick up occult prostate cancer due to a field defect the tumor exerts on normal tissue. The reported negative predictive value of Confirm MDX is high, ranging from 90-96% for low and high-grade cancer, respectively. In this study, we obtained MRI on all patients with a negative Confirm MDX to correlate imaging findings. We asked whether MRI can safely be omitted in the setting of a negative Confirm MDX.
INTRODUCTION AND OBJECTIVES:
There is an unmet need for methods to better identify patients most likely to benefit from repeat prostate biopsy after an initial negative biopsy. ConfirmMDx is a molecular test clinically validated for detection of prostate cancer (PCa) in tissue from PCa-negative biopsies. In this clinical utility study, we evaluated the impact of ConfirmMDx on the management of patients being considered for repeat prostate biopsy in a community urology practice.
METHODS: The study population consisted of 605 men with a prior PCa-negative prostate biopsy, who were counseled on the need to undergo repeat biopsy at a large community urology practice due to persistent elevated risk of PCa. All tissue cores from each PCanegative patient were tested with the ConfirmMDx methylationspecific PCR test, and positive or negative ConfirmMDx results based on the presence or absence of GSTP1, APC or RASSF1 methylation in the biopsy tissue. ConfirmMDx results were provided to the physician for use in repeat biopsy decision-making. Medical record review was conducted at a minimum of nine months after ConfirmMDx results were reported.
RESULTS: Of the 605 subjects enrolled, 308 (51%) had a negative ConfirmMDx test result and 297 (49%) were positive. For the entire study population, average age was 64 (median 64, interquartile range 59 to 69), average serum PSA level 6.8 ng/mL (5.7, 4.3 to 8.1). The median follow-up for both Confirm positives and negatives was 10 months post-testing. Repeat biopsy rates for ConfirmMDx positive and negative men were 32.3% (96/297) and 5.8% (15/308), respectively (P<0.001). For patients who received a biopsy during the follow-up period, the time between ConfirmMDx and repeat biopsy was shorter for ConfirmMDx positive men versus ConfirmMDx negatives (median 4 vs. 8 months, P[0.007).
CONCLUSIONS: In this utility study, ConfirmMDx had a significant impact on repeat prostate biopsy decision-making in a U.S. community urology setting. Repeat biopsy rates in ConfirmMDx positive men were six-fold higher than in ConfirmMDx negatives. These results reflect the clinical utility of ConfirmMDx for biopsy decision-making in real world clinical practice.
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MP24-03 RISK PREDICTION OF PROSTATE CANCER USING BASELINE PSA AND INHERITED GENETIC VARIANTS IN BLACK AND WHITE MEN
Mark Preston*, Kathryn Wilson, Boston, MA; Travis Gerke, Tampa, FL; Maxine Chen, Adam Kibel, Lorelei Mucci, Kathryn Penney, Boston, MA INTRODUCTION AND OBJECTIVES: Baseline PSA during midlife predicts lethal prostate cancer (PCa) with accuracy and can be used for risk-stratified screening. We sought to investigate how adjustment of baseline PSA levels for single nucleotide polymorphisms (SNPs) related to circulating PSA levels might improve prediction of aggressive PCa.
METHODS: We used the Physicians Health Study (PHS) and the Southern Community Cohort Study (SCCS) to identify men aged 40-70 yrs who had baseline PSA and SNP data. In the PHS, there were 392 white men with maximum 30 yr follow-up consisting of 145 aggressive PCa cases (Gleason >6, metastatic or fatal) with 121 controls plus 126 non-aggressive PCa cases as comparison. In the SCCS, there were 319 black men with maximum 12 yr follow-up consisting of 211 PCa cases and 108 controls. Baseline PSA>10 ng/ ml were excluded. Median and percentile PSA groupings were
